<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01975246</url>
  </required_header>
  <id_info>
    <org_study_id>1348.1</org_study_id>
    <nct_id>NCT01975246</nct_id>
  </id_info>
  <brief_title>Add-on to Micamlo BP Trial</brief_title>
  <official_title>An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Amlodipine 5 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a multi-centre, randomised, double-blind, active-controlled, parallel-group
      comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg
      +hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+
      amlodipine 5 mg (T80/A5 mg) in blood pressure lowering effect at week 8, the end of the
      double-blind period in essential hypertensive patients who fail to respond adequately to
      telmisartan 80 mg+ amlodipine 5 mg. Patients are assigned to one of the two groups after a
      6-week open-label run-in period taking T80/A5 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.</measure>
    <time_frame>baseline and week 8</time_frame>
    <description>Change from baseline in mean seated diastolic blood pressure (DBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.</measure>
    <time_frame>baseline and week 8</time_frame>
    <description>Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients With DBP&lt;90 mmHg and SBP&lt;140 mmHg as Seated Blood Pressure at Trough After 8 Weeks of the Double-blind Period</measure>
    <time_frame>baseline and week 8</time_frame>
    <description>Patients with trough seated DBP =&gt;90 mmHg or trough seated SBP &gt;=140 mmHg at baseline were analysed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">309</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan+amlodipine+HCTZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan+amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan + amlodipine</intervention_name>
    <description>FDC tablet</description>
    <arm_group_label>Telmisartan+amlodipine+HCTZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrochlorothiazide</intervention_name>
    <description>tablet</description>
    <arm_group_label>Telmisartan+amlodipine+HCTZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan + amlodipine</intervention_name>
    <description>FDC tablet</description>
    <arm_group_label>Telmisartan+amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo matching hydrochlorothiazide tablet</description>
    <arm_group_label>Telmisartan+amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs
             and mean seated diastolic blood pressure (DBP) must be &gt;=90 and &lt;=114 mmHg and mean
             seated systolic blood pressure (SBP) must be =&lt;200 mmHg

          -  Able to stop all current antihypertensive drugs (other than study medication) from
             Visit 1b through the end of the trial without risk to the patient based on the
             investigator's opinion

          -  Age 20 years or older

        Exclusion criteria:

          -  Patients with known or suspected secondary hypertension

          -  Patients with clinically relevant cardiac arrhythmia

          -  Congestive heart failure with New York Heart Association (NYHA) functional class
             III-IV

          -  Patients with recent cardiovascular events

          -  Patients with recent stroke events

          -  Patients with a history of sudden deterioration of renal function with angiotensin II
             receptor blockers or angiotensin converting enzyme inhibitors; or patients with
             post-renal transplant or post-nephrectomy

          -  Patients with hepatic and/or renal dysfunction

          -  Pre-menopausal women who are nursing or pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1348.1.015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atsubetsu-ku,Sapporo,Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiyoda-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiyoda-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiyoda-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku,Sapporo,Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itabashi-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itoshima, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Katsushika-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kishiwada, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiyose,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koto-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mihama-ku, Chiba, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miyagino-ku, Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moriya, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naka-ku,Yokohama,Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishi-ku, Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sakaide, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takamatsu, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1348.1.023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toshima-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2013</study_first_submitted>
  <study_first_submitted_qc>October 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2013</study_first_posted>
  <results_first_submitted>October 6, 2016</results_first_submitted>
  <results_first_submitted_qc>October 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2016</results_first_posted>
  <disposition_first_submitted>July 23, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>July 23, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 24, 2014</disposition_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study is randomised, double-blind, active-control, parallel-group comparison</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Telmisartan and Amlodipine+HCTZ</title>
          <description>Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet.</description>
        </group>
        <group group_id="P2">
          <title>Telmisartan+Amlodipine</title>
          <description>Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than stated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): The treated set consisted of all patients who were randomised to the double-blind period and took at least 1 dose of the randomised treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Telmisartan and Amlodipine+HCTZ</title>
          <description>Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet.</description>
        </group>
        <group group_id="B2">
          <title>Telmisartan+Amlodipine</title>
          <description>Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="149"/>
            <count group_id="B2" value="160"/>
            <count group_id="B3" value="309"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" spread="9.1"/>
                    <measurement group_id="B2" value="55.0" spread="9.7"/>
                    <measurement group_id="B3" value="54.7" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.</title>
        <description>Change from baseline in mean seated diastolic blood pressure (DBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.</description>
        <time_frame>baseline and week 8</time_frame>
        <population>Full analysis set (FAS): This analysis set was, conforming to the intent-to-treat principle, defined as all patients i) included in the treated set; and ii) taking measurements of seated DBP at reference baseline and at 1 or more time points during the double-blind period.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan and Amlodipine+HCTZ</title>
            <description>Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet.</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan+Amlodipine</title>
            <description>Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.</title>
          <description>Change from baseline in mean seated diastolic blood pressure (DBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.</description>
          <population>Full analysis set (FAS): This analysis set was, conforming to the intent-to-treat principle, defined as all patients i) included in the treated set; and ii) taking measurements of seated DBP at reference baseline and at 1 or more time points during the double-blind period.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="0.5"/>
                    <measurement group_id="O2" value="-4.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The last observation carried forward (LOCF) method was applied for missing data, where the value from the measurements at the closest preceding visit replaced the missing value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes baseline DBP as a linear covariate, and treatment and center as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>-2.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.</title>
        <description>Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.</description>
        <time_frame>baseline and week 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan and Amlodipine+HCTZ</title>
            <description>Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet.</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan+Amlodipine</title>
            <description>Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.</title>
          <description>Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. After patients had rested in a seated position for approximately 5 minutes, blood pressure was measured 3 times at approximately 2-minute intervals. The mean of the 3 measurements are used as endpoints.</description>
          <population>FAS</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.3" spread="0.8"/>
                    <measurement group_id="O2" value="-6.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The last observation carried forward (LOCF) method was applied for missing data, where the value from the measurements at the closest preceding visit replaced the missing value.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes baseline SBP as a linear covariate, and treatment and center as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.6</ci_lower_limit>
            <ci_upper_limit>-3.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients With DBP&lt;90 mmHg and SBP&lt;140 mmHg as Seated Blood Pressure at Trough After 8 Weeks of the Double-blind Period</title>
        <description>Patients with trough seated DBP =&gt;90 mmHg or trough seated SBP &gt;=140 mmHg at baseline were analysed.</description>
        <time_frame>baseline and week 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan and Amlodipine+HCTZ</title>
            <description>Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet.</description>
          </group>
          <group group_id="O2">
            <title>Telmisartan+Amlodipine</title>
            <description>Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With DBP&lt;90 mmHg and SBP&lt;140 mmHg as Seated Blood Pressure at Trough After 8 Weeks of the Double-blind Period</title>
          <description>Patients with trough seated DBP =&gt;90 mmHg or trough seated SBP &gt;=140 mmHg at baseline were analysed.</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" lower_limit="43.3" upper_limit="60.0"/>
                    <measurement group_id="O2" value="36.9" lower_limit="29.4" upper_limit="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Non-completers considered failure (NCF) method was applied for missing data, where missing data due to early discontinuation will be replaced as “failure” up to the planned final visit to be reached by all patients.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0051</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model includes treatment and center as fixed effects.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 24 hours after the last drug administration, up to 71 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Telmisartan and Amlodipine+HCTZ</title>
          <description>Subjects who were orally administered once daily with fixed dose combination (FDC) tablet of telmisartan 80 mg and amlodipine 5 mg+ hydrochlorothiazide (HCTZ) 12.5 mg tablet.</description>
        </group>
        <group group_id="E2">
          <title>Telmisartan+Amlodipine</title>
          <description>Subjects who were orally administered once daily with the fixed-dose combination tablet of telmisartan 80 mg and amlodipine 5 mg + placebo matching to hydrochlorothiazide 12.5 mg tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="149"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

